(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Defeating An inability to embrace success in Scholarly world: Individual Victories - 2Manual for 10 Scrumptious Specialty Mixed drinks
- 3Step by step instructions to Keep up with Great Hand Cleanliness Before Handshakes
- 4Finding the Universe of Computer generated Reality: Individual Encounters
- 5Influencers are selling a delusional fantasy of being postpartum. Why is it so easy to believe?
- Muslim Brotherhood stole half a billion dollars in Gaza donations, Arab sources reveal
- Vote in favor of Your #1 4K television: Lucidity and Drenching Matter
- Doggie diversity in size and shape began at least 11,000 years ago
- The Solution to Defeating Tarrying: Systems for Expanded Efficiency
- Taylor Momsen explains why she quit 'Gossip Girl': 'I really didn't want to be there'
- Manual for Vegetarian Protein Powder
- 7 Moves toward a Sound and Dynamic Way of life
- Hamas delegation meets Egypt’s spy chief amid mutual ceasefire violation claims
- More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
